Protokoly_diagnostiki_i_lechenia_zabolevany
.pdf, " % , , , n. facialis
" & :
1.*@ V 10 /2 ; 5 , 10
2.*? + 625 ; V 600
3. */ V 1000
4.*; V 5% 1
5.* 10 , 20 ; V 1%, 5% 1
6.*+ V 0,05% 1 ; 15
7.*< 3% 10-50
8.*B & 150 – 10 \ .
9.*_ 50 , 150 ; / 100
10.* 0,25
11.*+ 20 .
12.*7 70% ( )
13.* & 3% 25 , 40
" & & :
,- ! :
+ " # & 3 .- % " .
/ , & :
1.Otitis media with effusion. Ian Williamson. Search date March 2004. BMJ;
2.Kasemsuwan L, Clongsuesuek P. A double blind, prospective trial of topical ciprofloxacin versus normal saline solution in the treatment of otorrhoea. Clin Otolaryngol 1997; 22: 44-46;
3.Fradis M, Brodsky A, Ben David J, Srugo I, Larboni J, Podoshin L. Chronic otitis media treated topically with ciprofloxacin or tobramycin. Arch Otolaryngol Head Neck Surg 1997; 123: 1057-1060.
* – , # (% % ) .
|
|
R- - |
|
|||
: 21-171 |
|
|
|
|
||
"$ &: " |
|
|
|
|
||
: |
|
|
|
|
|
|
& |
! : |
" # " , |
|
|||
|
" |
|
( , |
), |
|
% |
% , |
|
|
, |
|
||
" . |
|
|
|
|
|
|
' & & ( ): 9 |
|
|
|
|||
(: S42.4 % " |
|
|
||||
) : R- – |
||||||
# " & |
" |
. |
|
|||
$ : |
|
|
|
|
||
1.( );
2.) .
? : |
|
|
||
? – ; |
|
|||
' – |
; |
|||
! – ; |
||||
% |
|
( : ?1 – & |
||
# , !3 – |
&" % |
|||
" ). |
|
|
||
* : &, % % , % |
||||
" |
: 3 |
|
||
|
|
|
: |
|
1.< " ;
2." % ;
3. |
B " |
( , , .); |
4. |
|
& |
" " ; |
|
|
5." " # ;
" & :
|
" ( . ); |
|
" 2 ; |
" & & :
1.7
2.#
3.# "
5.<
$# |
– $# . |
|
+ |
: |
|
J$ " |
. ? & " |
|
|
& &$ " 2 &. |
|
" :
1.# % "$ %3-6 ;
2." & " $ .
" & " .
" : " # # ( " #&$ Y- , ,-% .). &$ " % % " & . %
& |
% , " % &" |
|||||||
|
" |
. B |
|
|
" |
|
" |
|
3 . & |
|
" |
||||||
" 21 & |
, % " . |
|
|
|
||||
& |
|
|
, |
" |
& |
|||
|
|
" & & |
||||||
- & % . % & 3 |
: |
|||||||
1.% % 1 ., " .
2.% % 1 % % % # " & # .
3.J$ , % % % # " .
1-2 ( % & ), - % & . @
|
|
|
3 & |
"$ |
, $# - |
|
& . |
|
|
||||
! : |
|
|
||||
1. |
1-2 |
– |
3-4 |
\ 1,0-2,0; |
||
2. |
3 |
– |
3-4 |
\ 1,0-2,0 " 12 " (2 |
||
) 7 + 100 / " 8 " (3 ) 3-5 . |
||||||
" & : |
|
|
||||
1. |
*6 250 0,5 100 |
|||||
2. |
*/ V 250 , 500 , 1 000 |
|||||
|
|
|
|
|
|
|
3. |
*/ |
V 1000 |
||||
" & & : |
|
|||||
|
,- ! : |
|
|
|||
& " " 1,2,5$;
|
! & & |
" 2 ; |
|
' % & |
" " " 2-3 |
|
; |
|
' % & % " 6 & ; |
||
' " ;
% " .
/ , & :
1.Work Loss Data Institute. Shoulder.- 2005.- 137 p.
2.@ & . JB+BL>! B> > 6>+@?/BB $# " .- 6 , «-6 ».- 2002.- .523-524
3.National Guideline Clearinghouse. Practice Managment for Prophylactic Antibiotic Use in Open Fracture: Eastern Association for the Surgery of Trauma.- 2000.- p.28
4.G . " .- 6 , « -6 ».- 2002.- .576-577
5.National Guideline Clearinghouse. Preoperative Test: the Use of Routine Preoperative Tests for Elective Surgery: Evidence, Methods&Guidance. London.-NICE.- 2003. 108p.
6.National Guideline Clearinghouse. Elbow. Work Loss Data Institute.- 2004.- p.110
* – , # (% % ) .
|
A 8 , 8 |
: 06-060 |
|
"$ &: " |
|
: & |
|
& !: " |
|
' & & ( ): 12 |
|
(: K25 O % |
|
K28 $& |
|
K28.0 |
$& " |
K28.1 |
$& |
K28.2 |
$& " |
K28.4 |
$& " " " |
K28.5 |
$& " " |
K28.6 |
$& " " " |
|
|
) : ; « % », « & % », « "
&» |
$ |
$ |
D ;, |
$# |
" |
|
" |
|
|
; D ;, $# " |
||||
% |
" ( H. Pylori ). |
|
||
$ : – & , & , , |
|
|||
, & . – " . |
|
|||
* :
" , $ $ O<:
• & &
• " " & " & &
• |
% " |
|
|||
• " $ |
|
||||
• |
& |
|
- |
% & % |
# % |
• |
|
|
|
|
|
• " & Ig ?
• " : %$ & " %0(1), % & -.
•O< @ — HLA '5;
•% ,
•% " ?' ( O< 2,5 )
& : 3 & , , " ( , , " ). ' %$ &
O< & (+ '!).
" : 3
|
: , & % , , " |
|
& , ?@ " & " , & . |
" & & " # , ?@ % . /'@ %" . & – .
" & :
& " % &, 3 %$# " . > & % ,$ " $. ' "% .
: % @ : 44.41 %
: %$# " , " , &, & % , %& .
/ & : % % . ; . L % & , " % &
. % & " # %% & " , – . > & (?@100 . .), " # % % & " .
& # " % , V
" $# .
B / ( " 3000-4000$# & 5 $ 1,5-2 ). ". >% $ , , & , & 200-400 ,$ 400 , 5 , (5% $, -J ,!, ', ). @ / , /'@, " , " % % & V .
? .
@ 6 " & "
" |
|
. 0 " 3 , 4-5 & – 1 |
2 – 1. |
||
D " |
|
$ 2-3 &. + 3 |
& " &$ . K $: " – 4-5 , & – 10 &.
" & :
1. *; V 1% 1
2.*/ 250 , 500
3.*6 - 5 / 100
1.*$ 5%, 10% 400 , 500 ; 40% 5 , 10
4.*B V 100 6>/
5.*+ 0.9% -500
6.400 ,
7.*? V 5%, 10% 2 , 5
2. *; V 5% 1
8.* 10 , 20 ; V 1%, 5% 1
9.* 150 , 300 ; V 25 /
10.* , " (3 , % % )
11.*? V 50 /5
12.7 250
13.*+ V 0,05% 1 ; 15
14.*@ V 1% 1
15.*< 1%, 2% 10 , 20
16. *? , 5% - -100
" & & :
,- ! :
" ,
/ , & :
1.G : . ., ./ . J M.6., ! & '.!. 6.: 7 ;? 6>@B/B+?, 1998, 335-338;
2.http://www.rusmg.ru/, O & % 12- ;
3.J ;.J., O & % 12- , 2004.
* – , # (% % ) .
!
"
( " )
# 2006 .
#
: 09-107
"$ &: " :
& ! :
1.H & & % % .
2.' % ( "" % , % % ).
3. # % , # %$ " % & .
4.J " $# ( D ;).
5.@ % - .
6.H " " .
' & & : 12 .
(: L20.8 @ " L23 ? " L50 ? "
) : # – " % % , $#, $# , $# " , % % & IgE- ,$# , , .
$ :
I. .1. 3 ; 2. 3 ; 3. 3 . II. % : , % , % .
III. : % – 1 , # – 1 , " – 1 (1 – " , 2 – % , 3 – % " ). * : 1. " & ;
2.% " ;
3.;
4." ;
5.& # , &, & , & % ;
6.;
7.D ;.
" : , 3 " : % , .
5 :
1.# ;
2.# " ;
3.;
4.! .
:
1.% ;
2." ( 2 );
3. % % , % # 10 .
4." % % , ;
5.# & % ;
6." & , % " $